Arcus Biosciences Announces Upcoming Presentations at the 2019 American Association for Cancer Research Annual Meeting

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical
company focused on creating innovative cancer immunotherapies, today
announced seven presentations at the 2019 American Association for
Cancer Research (AACR) Annual Meeting being held March 29-April 3, 2019
in Atlanta, Georgia.

Details of Arcus’s Presentations are as follows:

ORAL PRESENTATION:

AB680 (small-molecule CD73 inhibitor)

Title: Development of potent and selective CD73 inhibitors:
Discovery and characterization of AB680
Date and Time: Saturday,
March 30, 2019, 9:30 AM - 9:55 AM
Location: Room A311

POSTER PRESENTATIONS:

AB928 (dual A_2aR/A_2bR
antagonist)

Title: Methods for assessment of the “adenosine fingerprint” in
clinical trials of AB928
Abstract Number: 3168
Date
and Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM
Location: Exhibit
Hall B, Poster Section: 21, Poster Board Number: 21

Title: Altered pan-Ras pathway and activating mutations in EGFR
result in elevated CD73 in multiple cancers
Abstract Number: 4980
Date
and Time: Wednesday, April 3, 2019, 8:00 AM - 12:00 PM
Location: Exhibit
Hall B, Poster Section: 24, Poster Board Number: 3

AB122 (anti-PD-1 antibody)

Title: Longitudinal monitoring of neoepitope-specific T cell
repertoires in patient blood following cancer immunotherapy
Abstract
Number: 4042
Date and Time: Tuesday, April 2, 2019, 1:00
PM - 5:00 PM
Location: Exhibit Hall B, Poster Section: 22,
Poster Board Number: 5

Title: Receptor occupancy and neo-epitope specific T-cell
repertoires in patients with solid tissue tumors following anti-PD-1
therapy
Abstract Number: 4100
Session Date and Time: Tuesday,
April 2, 2019, 1:00 PM - 5:00 PM
Location: Exhibit Hall
B, Poster Section: 24, Poster Board Number: 3

AB154 (anti-TIGIT antibody)

Title: Characterization of AB154, a humanized α-TIGIT antibody,
for use in combination therapies
Abstract Number: 1557
Session
Date and Time: Monday, April 1, 2019, 8:00 AM - 12:00 PM
Location: Exhibit
Hall B, Poster Section: 25, Poster Board Number: 26

AB474 (arginase inhibitor)

Title: AB474, a potent orally bioavailable inhibitor of arginase,
for the treatment of cancer
Abstract Number: 3862
Date
and Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM
Location:
Exhibit Hall B, Poster Section: 12, Poster Board Number: 12

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused
on creating innovative cancer immunotherapies. Arcus has several
programs targeting important immuno-oncology pathways, including a dual
adenosine receptor antagonist, AB928, which is in a Phase 1/1b program
to evaluate AB928 in combination with other agents in multiple tumor
types, and an anti-PD-1 antibody, AB122, which is being evaluated in a
Phase 1 trial and is being tested in combination with Arcus’s other
product candidates. Arcus’s other programs include AB154, an anti-TIGIT
antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy
and in combination with AB122, and AB680, a small-molecule inhibitor of
CD73, which is in a Phase 1 healthy volunteer study. Arcus has extensive
in-house expertise in medicinal chemistry, immunology, biochemistry,
pharmacology and structural biology. For more information about Arcus
Biosciences, please visit www.arcusbio.com.

Source: Arcus Biosciences

View source version on businesswire.com: https://www.businesswire.com/news/home/20190228005221/en/